Target intelligence / Profile preview

Pathogenic bacterium in the gut lumen

Molecular classification
Other
01

Overview

“Pathogenic bacteria in the gut lumen” is a broad, non-canonical designation referring to any bacterial species residing within the intestinal lumen that have the capacity to cause disease. This term does not refer to a single molecular target or receptor, but to a heterogeneous group of microorganisms. Prominent examples include *Clostridioides difficile*, *Salmonella enterica*, *Escherichia coli* (particularly certain pathogenic strains), *Shigella*, and *Campylobacter* species[2][4][5]. These bacteria employ various virulence factors—such as toxins, secretion systems, and immune evasion strategies—to colonize the gut, invade or disrupt the mucosal barrier, outcompete the beneficial commensal flora, and induce host disease processes. Therapeutic approaches typically rely on broad-spectrum or targeted antibiotics, but these interventions must be carefully managed due to collateral effects on the wider gut microbiota and the risk of selecting for antibiotic resistance[5][6]. The diversity of these pathogens and their dynamic interaction with both the host and the commensal microbiota complicates both the diagnosis and therapy for their associated diseases. Strictly, “pathogenic bacteria in the gut lumen” is not a proper molecular or receptor-based therapeutic target in current biomedical taxonomy—it refers to an entire class of disease-causing organisms rather than a druggable molecule or protein[2][5][6][7].

Other names
Pathogenic gut bacteriaintestinal pathogensgut pathogenic bacteriaenteric pathogens
02

Mechanism of action

Antibiotic inhibition of bacterial cell wall synthesis, inhibition of protein synthesis, disruption of DNA replication, competitive exclusion (probiotics), lysis by bacteriophages

03

Biological functions

Infectionhost invasionvirulencedisease causationimmune evasion
04

Disease associations

InfectionInflammationGastrointestinal diseasesSepsisOther
05

Safety considerations

Antibiotic resistancedisruption of commensal microbiota (dysbiosis)risk of exacerbating infection (e.g., antibiotics in EHEC)potential for triggering inflammatory or autoimmune disease
06

Interacting drugs

Antibiotics (e.g., metronidazole, vancomycin, ciprofloxacin, ceftriaxone)

2 more in the full profile.

07

Biomarkers

Presence of pathogen-specific DNA/RNA (PCR for toxins, e.g., C. difficile)antigen detectionstool culturesmetagenomic sequencing signatures

Beyond the preview

Go deeper on Pathogenic bacterium in the gut lumen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathogenic bacterium in the gut lumen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call